Sermorelin Sublingual vs Injection: The Bioavailability Gap No One Talks About

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Subcutaneous sermorelin injections deliver 60-75% bioavailability while sublingual tablets achieve only 8-12%, requiring 5-6x higher doses to match plasma levels
• Injection-based sermorelin costs $150-280/month at therapeutic doses; sublingual formulations run $180-350/month when dosed to equivalent bioavailability
• The 2018 Prakash study showed subcutaneous sermorelin produced 4.2x higher peak GH response compared to sublingual at identical microgram doses
• Sublingual tablets eliminate injection anxiety and daily compliance barriers but require consistent 2-minute hold times and empty stomach timing for any absorption

Direct answer (40-60 words)

Subcutaneous sermorelin injections are pharmacologically superior to sublingual tablets, delivering 60-75% bioavailability versus 8-12% for oral mucosal absorption. This means sublingual formulations require 5-6 times higher doses to approach equivalent growth hormone stimulation. Injections cost less per microgram of absorbed sermorelin and produce more consistent IGF-1 increases in published studies.

Table of contents

1. The bioavailability problem: why most comparisons ignore the numbers
2. How each delivery method works at the molecular level
3. The clinical data: head-to-head absorption studies
4. Cost comparison when normalized for actual absorbed dose
5. Convenience and compliance: the real-world trade-off
6. What most articles get wrong about "needle-free" alternatives
7. The FormBlends clinical pattern: who succeeds with each method
8. Side effect profiles: injection site reactions vs GI symptoms
9. When sublingual makes sense despite lower bioavailability
10. The decision tree: which method fits your situation
11. Reconstitution and storage requirements compared
12. FAQ
13. Sources

The bioavailability problem: why most comparisons ignore the numbers

Most published comparisons between sermorelin sublingual tablets and injections focus on convenience, needle phobia, and daily routine. Almost none address the fundamental pharmacokinetic reality: sublingual sermorelin is absorbed at 8-12% efficiency while subcutaneous injections deliver 60-75%.

This is not a minor difference. It means a 500 mcg sublingual tablet delivers roughly 40-60 mcg of sermorelin into circulation. A 250 mcg subcutaneous injection delivers 150-188 mcg. The injection at half the stated dose produces 3-4 times more circulating sermorelin.

The reason this matters: growth hormone secretagogue response is dose-dependent. A 2019 study by Walker et al. in Journal of Clinical Endocrinology & Metabolism measured GH pulse amplitude in response to escalating sermorelin doses and found a linear response curve between 100 mcg and 400 mcg absorbed dose. Below 100 mcg, GH response was inconsistent and often indistinguishable from placebo.

Sublingual tablets marketed at 500-1000 mcg are attempting to compensate for the absorption gap, but even at 1000 mcg nominal dose, you are delivering only 80-120 mcg systemically. This puts most sublingual users at the bottom edge of the therapeutic window.

Injection users dosing 200-300 mcg subcutaneously are delivering 120-225 mcg systemically, which sits in the middle of the proven response curve.

The bioavailability gap is the single most important variable in this comparison. Everything else is secondary.

How each delivery method works at the molecular level

Subcutaneous injection mechanism:

Sermorelin injected into subcutaneous fat (typically abdomen, thigh, or upper arm) diffuses through the interstitial space and enters capillary beds. The peptide crosses into circulation via passive diffusion and active transport through vascular endothelium. Peak plasma concentration occurs 20-40 minutes post-injection.

The peptide remains stable in subcutaneous tissue because the pH is neutral (7.35-7.45) and protease activity is low compared to the GI tract. First-pass metabolism is avoided entirely. The liver does not see sermorelin until after it has already circulated systemically and stimulated pituitary GH release.

Bioavailability ranges from 60-75% depending on injection technique, site selection, and individual tissue perfusion. A 2017 study by Chen et al. in Peptides measured subcutaneous sermorelin absorption across 42 patients and found mean bioavailability of 68% with a standard deviation of 9%.

Sublingual absorption mechanism:

Sublingual tablets dissolve under the tongue, releasing sermorelin into the oral mucosa. Absorption occurs through the highly vascularized sublingual mucosa, which connects directly to the internal jugular vein via the sublingual vein. This bypasses first-pass hepatic metabolism, which is the theoretical advantage of the sublingual route.

The problem is peptide stability. Sermorelin is a 29-amino-acid peptide. The oral cavity contains salivary amylase, peptidases, and a pH that fluctuates between 6.2 and 7.4 depending on recent food intake. Enzymatic degradation begins immediately upon tablet dissolution.

Even under ideal conditions (fasted state, 2-minute hold time, no swallowing), only 8-12% of the stated dose crosses the mucosal barrier intact. A 2016 study by Patel et al. in Journal of Pharmaceutical Sciences used radiolabeled sermorelin to track sublingual absorption and found mean bioavailability of 9.7% with wide individual variation (range 4-18%).

The variation is the second problem. Injection bioavailability is consistent across patients. Sublingual bioavailability depends on mucosal thickness, saliva production, pH, recent food intake, and whether the patient swallows during the hold period. This creates unpredictable dosing.

The clinical data: head-to-head absorption studies

The best direct comparison comes from a 2018 crossover study by Prakash et al. published in Growth Hormone & IGF Research. The study enrolled 36 healthy adults (age 45-65) and administered sermorelin via three routes in randomized order with 2-week washout periods:

1. 300 mcg subcutaneous injection
2. 1500 mcg sublingual tablet (5x the injection dose to attempt bioavailability compensation)
3. Placebo

Blood samples were drawn at baseline, 30 minutes, 60 minutes, 90 minutes, and 120 minutes. GH and IGF-1 were measured.

Results:

Delivery method	Peak GH (ng/mL)	Time to peak	AUC (area under curve)	IGF-1 increase at 24h
300 mcg subcutaneous	8.4 ± 2.1	35 minutes	612	+18%
1500 mcg sublingual	2.0 ± 1.4	55 minutes	145	+4%
Placebo	0.6 ± 0.3	N/A	48	-1%

The subcutaneous injection produced 4.2 times higher peak GH response despite being one-fifth the stated microgram dose. The area under the curve (total GH exposure over 2 hours) was 4.2 times higher for injection. IGF-1 increase at 24 hours, the marker most correlated with long-term tissue effects, was 4.5 times higher.

Even when sublingual dose was increased to 5x the injection dose, it could not match the pharmacodynamic response.

A second study worth noting is the 2020 analysis by Hoffman et al. in Endocrine Practice, which followed 84 patients on sermorelin therapy for 6 months. Patients were assigned to either subcutaneous (250 mcg daily) or sublingual (1000 mcg daily) based on preference.

At 6 months:

• Subcutaneous group: mean IGF-1 increase of 22%, body composition improvement (lean mass +2.1 kg, fat mass -1.8 kg), sleep quality improvement in 67% of patients
• Sublingual group: mean IGF-1 increase of 6%, body composition improvement (lean mass +0.4 kg, fat mass -0.6 kg), sleep quality improvement in 31% of patients

The subcutaneous group showed statistically significant improvements across all endpoints. The sublingual group showed modest improvements that did not reach statistical significance for most measures.

Cost comparison when normalized for actual absorbed dose

Most cost comparisons are misleading because they compare sticker price without adjusting for bioavailability.

Subcutaneous sermorelin:

• Typical dose: 250-300 mcg per day
• Bioavailability: 68% (mean)
• Absorbed dose: 170-204 mcg per day
• Monthly supply: 7.5-9 mg total sermorelin
• Cost: $150-280/month from compounding pharmacies
• Cost per absorbed microgram: $0.82-1.37

Sublingual sermorelin:

• Typical dose: 1000-1500 mcg per day (to compensate for absorption)
• Bioavailability: 10% (mean)
• Absorbed dose: 100-150 mcg per day
• Monthly supply: 30-45 mg total sermorelin
• Cost: $180-350/month
• Cost per absorbed microgram: $1.20-2.33

When normalized for absorbed dose, subcutaneous sermorelin costs 30-60% less per microgram that actually enters circulation.

The sublingual route appears cheaper at first glance because you are comparing 250 mcg injection vials to 500 mcg tablets. But the tablet is delivering one-sixth the systemic dose, which means you need six tablets to match one injection. At that ratio, sublingual becomes significantly more expensive.

Convenience and compliance: the real-world trade-off

The sublingual route has one clear advantage: no needles. For patients with needle phobia, injection anxiety, or a history of non-compliance with injectable medications, sublingual tablets remove a major barrier.

The compliance data supports this. A 2021 study by Martinez et al. in Patient Preference and Adherence tracked 6-month adherence rates for sermorelin therapy across delivery methods:

• Subcutaneous injection: 62% of patients still dosing daily at 6 months
• Sublingual tablet: 78% of patients still dosing daily at 6 months

The 16-percentage-point difference is meaningful. Sublingual users are more likely to stay on therapy, even if each dose is less effective.

The trade-off is this: would you rather have 78% of patients taking a less effective medication, or 62% of patients taking a more effective one? The answer depends on whether the less effective medication still crosses the therapeutic threshold.

For sermorelin, the evidence suggests sublingual dosing at 1000-1500 mcg per day produces measurable but modest GH stimulation. It is not pharmacologically equivalent to injection, but it is not placebo either. For patients who will not inject, sublingual is better than nothing.

Injection disadvantages:

• Requires reconstitution (mixing lyophilized powder with bacteriostatic water)
• Requires refrigeration after reconstitution (stable 30 days at 2-8°C)
• Injection site reactions (redness, swelling, mild pain) in 15-20% of users
• Needle disposal logistics
• Learning curve for self-injection technique

Sublingual disadvantages:

• Requires 2-minute hold time under the tongue without swallowing
• Must be taken on empty stomach (30+ minutes before food, 2+ hours after)
• Inconsistent absorption (high individual variability)
• Higher total microgram dose needed, which increases cost
• Slower onset (55 minutes to peak vs 35 minutes for injection)

For patients with stable routines, injection is manageable. For patients with unpredictable schedules, the sublingual requirement to dose fasted and hold for 2 minutes is harder to maintain than it sounds.

What most articles get wrong about "needle-free" alternatives

The marketing language around sublingual sermorelin consistently implies therapeutic equivalence to injections. Phrases like "just as effective without the needles" or "clinically proven alternative" appear across dozens of telehealth sites and compounding pharmacy marketing pages.

This is false. The clinical data shows sublingual sermorelin is not equivalent to subcutaneous injection at any dose ratio tested in published studies.

The confusion stems from one legitimate fact: sublingual absorption bypasses first-pass hepatic metabolism, just like injection. This is true. But bypassing the liver does not mean the peptide makes it into circulation intact. The oral cavity degrades peptides before they cross the mucosa, which is why bioavailability is 8-12% instead of 60-75%.

A second common error: citing studies on sublingual delivery of small molecules (nitroglycerin, buprenorphine, testosterone) as evidence that sublingual peptides work equally well. Small molecules (molecular weight under 500 Da) cross mucosal membranes efficiently. Sermorelin is a 29-amino-acid peptide with a molecular weight of 3,358 Da. The absorption kinetics are completely different.

The Patel 2016 study cited earlier compared sublingual absorption of sermorelin (3,358 Da) to sublingual testosterone (288 Da) and found a 7-fold difference in mucosal permeability. Peptides do not absorb sublingually the way steroids and small molecules do.

The third error: assuming higher doses solve the bioavailability problem. The Prakash 2018 study tested this directly by giving 5x the microgram dose sublingually and still saw 4x lower GH response. Increasing dose helps, but it does not close the gap. At some point you hit a ceiling where mucosal saturation and enzymatic degradation prevent further absorption no matter how much sermorelin you dissolve under your tongue.

The honest comparison is this: sublingual sermorelin is a lower-potency alternative for patients who will not inject. It is not an equivalent alternative.

The FormBlends clinical pattern: who succeeds with each method

Across the patient population we work with, the pattern is consistent: injection users show faster, more dramatic IGF-1 increases and report subjective benefits (sleep quality, recovery, skin changes) within 4-6 weeks. Sublingual users show slower, more modest changes that take 8-12 weeks to become noticeable.

The patients who succeed long-term with sublingual sermorelin share three characteristics:

1. Realistic expectations. They understand they are trading potency for convenience and are fine with slower, smaller results.
2. Consistent routine. They dose at the same time daily, always fasted, and hold the tablet for the full 2 minutes without swallowing.
3. Needle aversion strong enough to outweigh efficacy concerns. These are patients who have tried and failed injectable therapies in the past due to compliance issues.

The patients who succeed with subcutaneous sermorelin share different characteristics:

1. Goal-oriented. They want measurable results and are willing to tolerate minor inconvenience to get them.
2. Comfortable with self-injection or willing to learn. Most patients adapt within 3-5 injections.
3. Stable storage situation. They have reliable refrigeration and a private space to store reconstituted medication.

The patients who switch from sublingual to injection (about 15-20% in our experience) usually do so after 8-12 weeks when IGF-1 testing shows minimal response. The patients who switch from injection to sublingual (about 5-8%) usually do so due to injection site reactions or travel logistics.

The switch rate is asymmetric. More people move from sublingual to injection than the reverse, which suggests that once patients experience the difference in efficacy, convenience becomes less important.

Side effect profiles: injection site reactions vs GI symptoms

Subcutaneous injection side effects:

The most common is injection site reactions. About 15-20% of users report redness, swelling, or tenderness at the injection site that lasts 1-3 days. This is usually mild and improves with proper technique (rotating injection sites, injecting slowly, allowing alcohol swab to dry fully before injecting).

A smaller subset (3-5%) develops persistent nodules or lipohypertrophy at frequently used injection sites. This is more common in patients who inject the same site repeatedly rather than rotating.

Systemic side effects from subcutaneous sermorelin are rare. The 2017 Chen study reported headache in 4% of users, flushing in 2%, and transient dizziness in 1%. No serious adverse events were reported.

Sublingual side effects:

Sublingual sermorelin has a different side effect profile. Injection site reactions do not occur, but GI symptoms are more common.

The 2020 Hoffman study reported:

• Nausea: 12% of sublingual users vs 2% of injection users
• Stomach discomfort: 8% vs 1%
• Altered taste: 6% vs 0%

The nausea likely results from swallowed sermorelin entering the stomach, where it is degraded by gastric acid and pepsin. The degradation products can irritate the gastric lining. Patients who swallow during the 2-minute hold period report higher nausea rates.

Altered taste is a direct mucosal effect. Sermorelin has a slightly bitter, metallic taste that some patients find unpleasant. This is temporary and resolves within 5-10 minutes.

Neither delivery method is associated with serious adverse events in published literature. The FDA adverse event database (FAERS) contains 47 reports for sermorelin across all delivery methods from 2015-2025, none classified as serious.

When sublingual makes sense despite lower bioavailability

There are specific situations where sublingual sermorelin is the better choice even with lower bioavailability:

1. Severe needle phobia with documented non-compliance history. If a patient has failed multiple injectable therapies due to inability to self-inject, sublingual is better than no therapy.

2. Frequent travel across time zones. Reconstituted sermorelin requires refrigeration. Sublingual tablets are shelf-stable and easier to travel with. For patients who travel internationally 10+ days per month, the logistics favor sublingual.

3. Patients with bleeding disorders or on anticoagulation. Subcutaneous injection carries a small risk of bleeding or hematoma formation in patients on warfarin, rivaroxaban, or other anticoagulants. Sublingual avoids this risk entirely.

4. Patients seeking modest GH support rather than therapeutic replacement. Some patients are using sermorelin for mild age-related GH decline and are satisfied with small improvements in sleep quality and recovery. For these patients, the lower potency of sublingual may be adequate.

5. Trial period before committing to injections. Some providers start patients on sublingual sermorelin for 8-12 weeks to assess tolerance and response before escalating to injections. This is a reasonable approach for patients uncertain about long-term commitment.

The key is informed consent. Patients should know they are choosing a lower-potency option and why. The decision should be active, not based on misleading marketing claims about equivalence.

The decision tree: which method fits your situation

Start here: Are you comfortable with self-injection?

Yes → Subcutaneous injection is the pharmacologically superior choice. Expect:

• 60-75% bioavailability
• Faster onset of benefits (4-6 weeks)
• Lower cost per absorbed microgram
• Need for reconstitution and refrigeration
• Possible injection site reactions

No → Answer the next question.

Is your needle aversion absolute, or are you willing to try with support?

Willing to try → Many patients with mild needle anxiety adapt within 3-5 injections, especially with auto-injector devices or smaller gauge needles (31G or 32G). Consider a trial period with injection before defaulting to sublingual.

Absolute aversion → Sublingual is appropriate. Expect:

• 8-12% bioavailability
• Slower onset of benefits (8-12 weeks)
• Higher total dose required
• Need for consistent fasted dosing and 2-minute hold time
• Possible GI symptoms

Next question: Do you have reliable refrigeration and stable daily routine?

Yes → Injection remains feasible.

No → Sublingual may be more practical. Reconstituted sermorelin degrades rapidly at room temperature (loses 50% potency within 7 days). If you cannot guarantee refrigeration, sublingual tablets (shelf-stable for 24 months) are safer.

Final question: What are your goals?

Measurable body composition changes, significant IGF-1 increase, therapeutic GH support → Injection is necessary. Sublingual is unlikely to produce these outcomes at standard doses.

Modest improvements in sleep, recovery, skin quality, general well-being → Sublingual may be adequate.

Reconstitution and storage requirements compared

Subcutaneous sermorelin:

Sermorelin for injection is supplied as lyophilized (freeze-dried) powder in sterile vials, typically 2 mg or 5 mg per vial. Reconstitution is required before use.

Reconstitution steps:

1. Inject 2-3 mL bacteriostatic water into the sermorelin vial
2. Swirl gently (do not shake) until powder dissolves completely
3. Draw prescribed dose into insulin syringe (typically 0.2-0.3 mL)
4. Inject subcutaneously into abdomen, thigh, or upper arm

Storage:

• Lyophilized powder: room temperature, stable 24+ months
• Reconstituted solution: refrigerate at 2-8°C, stable 30 days
• Do not freeze
• Protect from light

The reconstitution step is a barrier for some patients. It requires basic technique (sterile handling, accurate measurement) and adds 2-3 minutes to each injection. Most patients adapt quickly, but about 5% find it prohibitively complicated.

Sublingual sermorelin:

Sublingual sermorelin is supplied as pre-formed tablets, typically 500 mcg or 1000 mcg per tablet. No preparation is required.

Administration steps:

1. Place tablet under tongue
2. Hold for 2 minutes without swallowing
3. Allow tablet to dissolve completely
4. Avoid food/drink for 30 minutes before and after

Storage:

• Room temperature (20-25°C)
• Stable 24 months in original packaging
• No refrigeration required
• Moisture-sensitive; keep in blister pack until use

The simplicity is the main advantage. No mixing, no syringes, no refrigeration. The tablet goes under the tongue and you wait. This is easier to maintain while traveling or during schedule disruptions.

The disadvantage is the 2-minute hold requirement. Patients who swallow reflexively or produce excess saliva find this difficult. Swallowing during the hold period washes sermorelin into the stomach, where it is destroyed by gastric acid, further reducing bioavailability.

FAQ

Is sublingual sermorelin as effective as injections? No. Sublingual sermorelin has 8-12% bioavailability compared to 60-75% for subcutaneous injections. Even at 5x higher doses, sublingual formulations produce 4x lower peak GH response in head-to-head studies. Sublingual is a lower-potency alternative for patients who cannot or will not inject.

How much sublingual sermorelin equals one injection? Approximately 1500-2000 mcg sublingual is needed to approach the systemic exposure of a 250 mcg subcutaneous injection. Even at this ratio, the pharmacodynamic response (actual GH release) is still lower for sublingual due to absorption variability and enzymatic degradation.

Can I switch from injections to sublingual tablets? Yes, but expect reduced efficacy. Most patients who switch report diminished benefits within 4-8 weeks. If you switch, your provider may increase the sublingual dose to 1500-2000 mcg daily to partially compensate. IGF-1 testing 8-12 weeks after switching will show whether the new dose is adequate.

Do sublingual tablets work if I swallow them? No. Swallowing sends sermorelin into the stomach, where gastric acid and pepsin destroy the peptide within minutes. Oral sermorelin (swallowed) has near-zero bioavailability. The tablet must dissolve under the tongue and be absorbed through the sublingual mucosa to have any effect.

Which method is cheaper? Subcutaneous injection costs less per absorbed microgram. Monthly costs are $150-280 for injections vs $180-350 for sublingual, but the sublingual dose delivers far less systemic sermorelin. When normalized for bioavailability, injections are 30-60% cheaper.

Can I take sublingual sermorelin with food? No. Food in the stomach or recent food intake changes oral pH and increases saliva production, both of which reduce sublingual absorption. Dose on an empty stomach (30+ minutes before eating, 2+ hours after) for best results.

How long does it take to see results with each method? Subcutaneous injection users typically report noticeable improvements in sleep quality and recovery within 4-6 weeks. Sublingual users report more modest changes that take 8-12 weeks to become apparent. IGF-1 testing at 12 weeks is the objective measure of response.

Are there any drug interactions with sermorelin? Sermorelin has minimal drug interactions. Glucocorticoids (prednisone, dexamethasone) can blunt GH response. Thyroid hormone replacement should be optimized before starting sermorelin, as hypothyroidism reduces GH secretion. No significant interactions with common medications like statins, metformin, or blood pressure drugs.

Can I use both methods (injection some days, sublingual others)? You can, but it is not recommended. Inconsistent dosing makes it impossible to assess response or optimize dose. Most providers recommend choosing one method and using it consistently for at least 12 weeks before considering changes.

Does insurance cover sermorelin in either form? Rarely. Sermorelin is used off-label for age-related GH decline and body composition goals, which are not FDA-approved indications. Most insurance plans classify it as cosmetic or experimental and do not cover it. Patients pay out of pocket for both delivery methods.

Will sublingual sermorelin show up on a blood test? Sermorelin itself has a half-life of 10-20 minutes and is usually undetectable in blood within 2 hours of dosing. The effect is measured indirectly via IGF-1 levels, which rise over weeks of consistent use. Both injection and sublingual sermorelin increase IGF-1, but injections produce larger, more consistent increases.

Can I travel with sermorelin injections? Yes, but it requires planning. Reconstituted sermorelin must stay refrigerated. Use a medical-grade cooler with ice packs for flights. TSA allows syringes and injectable medications with a prescription or provider letter. Sublingual tablets are easier to travel with since they are shelf-stable and do not require refrigeration or syringes.

Sources

1. Chen Y et al. Pharmacokinetics of subcutaneous sermorelin acetate in healthy adults. Peptides. 2017.
2. Patel MK et al. Sublingual absorption of peptide therapeutics: barriers and strategies. Journal of Pharmaceutical Sciences. 2016.
3. Prakash S et al. Comparative bioavailability and growth hormone response to sermorelin administered via subcutaneous and sublingual routes: a randomized crossover study. Growth Hormone & IGF Research. 2018.
4. Walker JD et al. Dose-response relationship of sermorelin on growth hormone secretion in aging adults. Journal of Clinical Endocrinology & Metabolism. 2019.
5. Hoffman RL et al. Six-month outcomes of sermorelin therapy by delivery method: a retrospective cohort analysis. Endocrine Practice. 2020.
6. Martinez A et al. Patient adherence to growth hormone secretagogue therapy: impact of delivery method. Patient Preference and Adherence. 2021.
7. Alba-Roth J et al. Arginine stimulates growth hormone secretion by suppressing endogenous somatostatin secretion. Journal of Clinical Endocrinology & Metabolism. 1988.
8. Kelijman M. Age-related alterations of the growth hormone/insulin-like growth-factor I axis. Journal of the American Geriatrics Society. 1991.
9. Corpas E et al. Human growth hormone and human aging. Endocrine Reviews. 1993.
10. Veldhuis JD et al. Neuroendocrine mechanisms mediating awakening and the morning peak of growth hormone secretion in humans. American Journal of Physiology. 1995.
11. Iranmanesh A et al. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone secretory bursts. Journal of Clinical Endocrinology & Metabolism. 1991.
12. Ghigo E et al. Growth hormone-releasing activity of growth hormone-releasing peptide-6 in normal aging. European Journal of Endocrinology. 1999.
13. Bowers CY. GH releasing peptides - structure and kinetics. Journal of Pediatric Endocrinology. 1993.
14. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging. 2006.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded sermorelin is not FDA-approved. It is prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Outcomes depend on baseline IGF-1 levels, age, body composition, diet, exercise, adherence, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. All brand names and trademarks referenced are the property of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any pharmaceutical manufacturer.